GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shortwave Life Sciences PLC (AQSE:PSY) » Definitions » Current Deferred Revenue

Shortwave Life Sciences (AQSE:PSY) Current Deferred Revenue : £0.00 Mil (As of . 20)


View and export this data going back to 2022. Start your Free Trial

What is Shortwave Life Sciences Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Shortwave Life Sciences's current deferred revenue for the quarter that ended in . 20 was £0.00 Mil.

Shortwave Life Sciences Current Deferred Revenue Historical Data

The historical data trend for Shortwave Life Sciences's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shortwave Life Sciences Current Deferred Revenue Chart

Shortwave Life Sciences Annual Data
Trend
Current Deferred Revenue

Shortwave Life Sciences Semi-Annual Data
Current Deferred Revenue

Shortwave Life Sciences Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Shortwave Life Sciences's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Shortwave Life Sciences Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
17 Hanover Square, London, GBR, W1S 1BN
Shortwave Life Sciences PLC is a biopharmaceutical company focused in advancing pioneering therapies in mental health care, also it is involved in developing novel drug combinations and delivery methods to treat patients suffering from mental health disorders. It identifies, operates and creates value from early-stage, breakthrough initiatives, with an initial focus on eating disorders.

Shortwave Life Sciences Headlines